IPS HEART
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy
  • More
    • Home
    • About Us
    • Our Approach
    • Our Pipeline
    • Why Heart Disease?
    • Why DMD?
    • Platform
    • Publications
    • Clinical Efficacy
IPS HEART

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

ABOUT US

We are committed to transforming the lives of patients suffering devastating diseases with no cure. From heart disease to Duchenne muscular dystrophy, we tackle the most challenging conditions head on.

IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States. 

IPS HEART replicated its pioneering small molecule IPS platform approach in a second disease by publishing for the first time new dystrophin + skeletal muscle for Duchenne Muscular Dystrophy. 


IPS HEART is the only IPS company to have published strong efficacy in two difficult diseases by creating new cardiac muscle and skeletal muscle for both heart disease and DMD. 

Copyright © 2014 IPS HEART - All Rights Reserved.